FindTrial
Sign In

Selinexor 60 mg

DRUG3 trials

Sponsors

Karyopharm Therapeutics Inc, Hackensack Meridian Health

Conditions

Colorectal Cancer (CRC)Mild ThrombocytopeniaModerate ThrombocytopeniaMultiple MyelomaMyelofibrosisNon-Small Cell Lung Carcinoma (NSCLC)Other Solid Tumors

Phase 1

Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment
CompletedNCT04256707
Karyopharm Therapeutics IncColorectal Cancer (CRC), Non-Small Cell Lung Carcinoma (NSCLC), Other Solid Tumors
Start: 2020-01-14End: 2024-07-31Updated: 2025-03-19

Phase 2

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
SuspendedNCT04661137
Hackensack Meridian HealthMultiple Myeloma
Start: 2021-03-16End: 2027-02-01Target: 96Updated: 2026-02-10
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
RecruitingNCT05980806
Karyopharm Therapeutics IncMild Thrombocytopenia, Moderate Thrombocytopenia, Myelofibrosis
Start: 2024-04-22End: 2028-10-01Target: 58Updated: 2026-02-12

Related Papers

Updated results from phase 2b study of selinexor in combination with carfilzomib, daratumumab, or pomalidomide in patients with multiple myeloma (MM) relapsing on current therapy.
Journal of Clinical Oncology2025-05-28
A Phase 2b Study of Selinexor in Combination with Pomalidomide in Patients with Pomalidomide-Refractory Multiple Myeloma
Blood2024-11-05
Phase 2 study evaluating selinexor monotherapy in patients with JAKi-naïve myelofibrosis and moderate thrombocytopenia.
Journal of Clinical Oncology2024-06-011 citations
A Phase 2b Study of Selinexor in Combination with Carfilzomib, Daratumumab, or Pomalidomide in Patients with Multiple Myeloma Relapsing on Current Therapy
Blood2023-11-021 citations
A phase IIb study of selinexor in combination with carfilzomib, daratumumab, or pomalidomide in patients with multiple myeloma relapsing on current therapy.
Journal of Clinical Oncology2023-06-01
Open-label phase 1/2 study evaluating the tolerability and antitumor activity of selinexor and pembrolizumab in colorectal cancer.
Journal of Clinical Oncology2022-01-191 citations
Open-label phase 1 study evaluating the tolerability and anti-tumor activity of selinexor and pembrolizumab in colorectal cancer.
Journal of Clinical Oncology2021-05-202 citations